PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Launched by PROSTATE CANCER CLINICAL TRIALS CONSORTIUM · Jul 29, 2021
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The PROMISE Registry is a research study focused on prostate cancer, aiming to gather information about patients who have specific genetic changes linked to the disease. The goal is to better understand how these genetic changes affect treatment outcomes and survival rates. The study will enroll around 5,000 men with confirmed prostate cancer, regardless of the stage of their disease, over the next five years. Eligible participants must have a diagnosis confirmed by a tissue biopsy, a high PSA level, or clear imaging evidence of the cancer. They must also reside in the United States or certain territories.
Participants in this study will provide a saliva sample for genetic testing and complete a survey about their health and family history. If any significant genetic changes are found, they will have a chance to discuss these results with a genetic counselor. Throughout the study, participants will receive updates on new treatments and research opportunities related to their condition and will be followed for at least 15 years to track their health and outcomes. This research aims to empower patients with information that could lead to better treatment options tailored to their individual genetic makeup. For more information, you can visit the study website at prostatecancerpromise.org.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- * Have prostate cancer (any stage of disease or survivorship) diagnosed or documented through one of the following:
- • tissue biopsy, and/or
- • PSA greater than 100 ng/dL (1ng/ml), and/or
- • clear radiographic evidence of disease
- • Live in the United States (including Puerto Rico, Guam, American Samoa, US Virgin Islands, Northern Mariana Islands)
- Exclusion Criteria:
- • Unable or unwilling to provide all of the necessary information for eligibility
- • Incomplete inclusion criteria
About Prostate Cancer Clinical Trials Consortium
The Prostate Cancer Clinical Trials Consortium is a leading organization dedicated to advancing the understanding and treatment of prostate cancer through innovative clinical research. Comprising a network of esteemed academic institutions and research centers, the consortium facilitates collaborative efforts to design and implement rigorous clinical trials aimed at evaluating novel therapies and treatment strategies. By fostering partnerships among researchers, clinicians, and industry stakeholders, the consortium strives to improve patient outcomes and enhance the quality of care for individuals affected by prostate cancer. Its commitment to scientific excellence and patient-centered research positions it at the forefront of efforts to combat this prevalent disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Seattle, Washington, United States
Baltimore, Maryland, United States
Patients applied
Trial Officials
Heather Cheng, MD, PhD
Principal Investigator
Fred Hutchinson Cancer Center
Channing Paller, MD
Principal Investigator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials